pdufa.bio
CalendarDecisionsApprovals/yrTrial oddsLearnResearchMethodology
Home › PDUFA Calendar › BIIB

BIIB PDUFA Date: LEQEMBI IQLIK (lecanemab-irmb)(at-home injection)

FDA decision (PDUFA) target 2026-08-24 · Biogen Inc. · Early Alzheimer's disease (AD) a-home injection

BIIB run-up into the PDUFA (last ~120 days)

$204.53$172.34
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-08-24
Drug / candidateLEQEMBI IQLIK (lecanemab-irmb)(at-home injection)
IndicationEarly Alzheimer's disease (AD) a-home injection
CompanyBiogen Inc.
Market-cap tierLarge
Cohort decision-day move (history)±1% median
ClinicalTrials.govNCT03887455 · active

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

Track this live → price, options (expected move & IV) and the full dashboard
Opens the pdufa.bio app (private beta)

FAQ

When is the BIIB PDUFA date?
The FDA PDUFA target date for BIIB (Biogen Inc.) is 2026-08-24 for LEQEMBI IQLIK (lecanemab-irmb)(at-home injection). Dates are company/FDA-sourced and can slip — verify against primary filings.
What is BIIB's drug LEQEMBI IQLIK (lecanemab-irmb)(at-home injection)?
LEQEMBI IQLIK (lecanemab-irmb)(at-home injection) is Biogen Inc.'s candidate under FDA review for Early Alzheimer's disease (AD) a-home injection.
What typically happens to a large-cap stock into a PDUFA date?
Historically, large-cap names had a median decision-day move around ±1% (694-PDUFA cohort, 2024–26). This is historical context by market-cap tier, not a prediction for this drug.